news Protein activation discovery could widen access to cancer immunotherapy 8 July 2021 | By Anna Begley (Drug Target Review) The activation of the protein p53 was shown to boost immune responses against cancer tumours in mice in a new study, potentially widening access to immunotherapy.
news Novel DNA-based COVID-19 vaccines induce immune responses in mice 5 February 2021 | By Hannah Balfour (Drug Target Review) The DREP-S vaccine candidate was found to be the most potent of the two investigational vaccine prototypes, eliciting high titers of SARS-CoV-2 neutralising antibodies after a single dose.
news Biomarker in blood could determine severity of COVID-19 27 January 2021 | By Victoria Rees (Drug Target Review) A study has shown that patients with severe COVID-19 have significantly elevated levels of M-MDSCs in their blood compared with healthy individuals.
news Novel nanobody combinations protect cells from SARS-CoV-2 in vitro 14 January 2021 | By Hannah Balfour (Drug Target Review) By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
article Developing nanobodies and sybodies to combat COVID-19 13 November 2020 | By Hannah Balfour (Drug Target Review) Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
news Study shows MAIT cells highly engaged in the immunological response to COVID-19 29 September 2020 | By Victoria Rees (Drug Target Review) New research has shown that MAIT cells are strongly activated in people with moderate to severe COVID-19 disease.
news Nanobody could be used as antiviral treatment against COVID-19 4 September 2020 | By Victoria Rees (Drug Target Review) Researchers have found a nanobody named Ty1 that neutralises SARS-CoV-2 by attaching itself to the Spike protein of COVID-19.
news Decoy ACE2 receptors could be promising COVID-19 infection-preventing drug 3 April 2020 | By Hannah Balfour (Drug Target Review) Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
news Brain Atlas enables exploration of the brain proteome 6 March 2020 | By Hannah Balfour (Drug Target Review) International researchers have analysed nearly 1,900 brain samples to create the Brain Atlas, the latest database released by the Human Protein Atlas (HPA) project.
news Gene found to protect motor neurons against degeneration 19 February 2020 | By Mandy Parrett (Drug Target Review) Results of an international collaboration show promise for the future of motor neurone disease treatment efforts, as protective gene is identified.
news Could Frizzled receptors be the target of new cancer therapeutics? 23 January 2020 | By Hannah Balfour (Drug Target Review) The G-protein coupled receptor Frizzled, implicated in diseases like cancer, can be targeted with small molecules which could provide the basis for anti-cancer therapeutics, according to researchers.
news Researchers use CRISPR to identify proteins that prevent inflammation 21 January 2020 | By Victoria Rees (Drug Target Review) New findings using CRISPR have shown that the IL-4 and IL-13 proteins can protect the body against inflammation from autoimmune diseases.
news PCSK6 enzyme plays a key role in vascular disease, according to research 20 January 2020 | By Hannah Balfour (Drug Target Review) A new study has demonstrated that the enzyme proprotein convert subtilisin/kexin 6 causes structural and functional remodelling in vascular disease, so could be a new therapeutic target.
news Study shows cheap drug could alleviate treatment-resistance in leukaemia 20 January 2020 | By Rachael Harper (Drug Target Review) A clinical study is to be launched after researchers found that a common and inexpensive drug may be used to counteract treatment resistance in patients with AML.
news Study shows new strategies for HIV control 23 December 2019 | By Drug Target Review New research goes against the paradigm of HIV control that focuses on killing off infected cells and supports a model in which viral suppression could possibly serve as a cure.
